Provider review, September 2026
NexLife lists two peptide products and neither one can be bought. One shows a real list price above a sold-out control; the other shows a zero. The company also carries an FDA warning letter that names this exact domain.
NexLife also sells 1 compound this site boards without publishing a price for it: PT-141.
NexLife is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The growth-hormone peptide has a product page with a regular price printed as visible text, and the word sold out printed twice — once as a status line and once where the buy control would be.
That figure is genuinely published. It is also, today, a price for something nobody can order, and this record says so in the row itself rather than letting the number stand alone on a comparison board.
The page names no strength, no quantity and no billing period. So this is a one-off list price, not a monthly programme rate, and it is filed as such — a figure that looks cheap beside a monthly rate is not cheap, it is a different kind of number.
It was read twice in the same session, in two separate browser contexts, and reproduced both times.
The other peptide product page renders a regular price of zero, and sold out beneath it. There is no description, no dose and no strength.
A zero is a storefront default. It is what a product record looks like when nobody has set a price on it, and it is not a figure the seller is asking anyone to pay.
This record declares the compound, because a product page for it exists, and deliberately carries no price row. A zero recorded as a price would sort to the top of a board and describe an offer that does not exist.
The rest of the catalogue — the plan pages, the funnels, the collections — is compounded GLP-1 and one hair product. The peptide range is these two pages.
The regulator's live index returns an exact match on this company's registered name, and the letter body names this site's own web address as the content reviewed. Reference number, issue date and address are all on the row.
The FAQ's opening line claims care across all fifty states. The safety disclosure lower on the same page says instead that the platform serves eligible patients across the United States through affiliated medical groups, which counts nothing. This record takes the fifty-state sentence, because it is the one that makes a claim.
The answers that would name the compounding pharmacies and the prescribers sit inside collapsed controls that did not open on repeated attempts across separate sessions. What is visible without them is that every pharmacy holds certifications — a statement about a standard, not about a supplier.
Nothing anywhere mentions lab work.
NexLife received an FDA warning letter issued June 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxNot today. Both product pages are marked sold out.
No. The page names no billing period, no strength and no quantity, so it is a one-off list price.
Because its page publishes a zero, which is a storefront default rather than an offer.
Yes. It names the company by its registered name and names this site's own web address as the content the regulator reviewed.
No. The visible answer is that every pharmacy it uses holds certifications, which describes a standard rather than a supplier.
NexLife is not a paid partner; this link may earn a commission if that changes. Full disclosure.